Telix at ANZSNM 2023
25 May 2023
Join Telix in Adelaide, South Australia, for the 53rd Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine from the 26th to the 28th of May.
We are pleased to support the premier event for nuclear medicine in Australia with a range of Telix investigational assets featured in presentations across the weekend.
Our team will be at booths #13 and #15 to share more on our approved PSMA-PET imaging agent for prostate cancer and the diagnostic and therapeutic solutions we are developing as part of our industry-leading theranostic pipeline.
ANZSNM presentation details are as follows (all times ACST):
Fireside Chat with Associate Professor Brian Shuch MD
Date and Time: Friday, May 26, 7:30pm
Title: The Molecular Biopsy? New Frontiers of ImmunoPET Imaging in Renal Cell Carcinoma
Register here
Oral Presentations
Date and Time: Saturday 27 May, 3.00pm – 3.15pm
Title: 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma – results from phase III ZIRCON study
Presenter: Prof. Andrew Scott AM (Austin)
Date and Time: Saturday 27 May, 1.45pm – 2.00pm
Title: Addition of DNA dependent protein kinase (DNA-PK) inhibitor peposertib enhances efficacy of 177Lu-based radioimmunotherapy in pre-clinical models of prostate and renal cell carcinoma
Presenter: Prof. Andrew Scott AM (Austin)
Poster Presentations
Title: A multi-centre evaluation of the 177Lu SPECT/CT calibration process for the ProstACT TARGET study
Presenter: Quan Boon Lee, PhD (GenesisCare)
Title: External beam therapy with theranostic radioligand therapy for oligometastatic Prostate Cancer (ProstACT TARGET)
Presenter: Prof. Nat Lenzo, MD (GenesisCare)
Title: 177Lu-TLX591 safety, biodistribution and dosimetry study (ProstACT SELECT)
Presenter: Shams Arifeen, Telix
Title: Are monoclonal antibodies suitable in Targeted Radionuclide Therapy using alpha emitters?
Presenter: Divesh Kumar, Telix
Title: APOMAB® as a theranostic tool in cancer treatment
Presenter: Alex Staudacher, PhD (University of Adelaide)
Title: Manufacturing of [89Zr]-DFOSq-APOMAB® for first-in-human clinical trial
Presenter Hiu Lam, PhD (University of Adelaide)